Introduction
============

Cardiovascular disease (CVD) is the leading cause of human mortality worldwide. The prevalence and incidence of coronary heart disease (CHD) is increasing in numerous countries, including China ([@b1-mmr-08-01-0260]). CHD is a complex disease that involves a variety of genetic and environmental factors. Increased concentrations of low-density lipoprotein cholesterol (LDL-C) in the blood is a well-established risk factor for CHD ([@b2-mmr-08-01-0260]) and the primary target for lipid-lowering therapy in the prevention and treatment of CVD ([@b3-mmr-08-01-0260]).

Apolipoprotein B (apoB) is the main apolipoprotein component of LDL-C and is important in the transport and metabolism of LDL-C. *APOB* gene variants (including rs562338 and rs503662) have been shown to be associated with an increased concentration of LDL-C in European and American populations ([@b2-mmr-08-01-0260],[@b4-mmr-08-01-0260],[@b5-mmr-08-01-0260]). High levels of plasma apoB and LDL-C were also shown to increase the risk of CVD ([@b6-mmr-08-01-0260]). A number of studies recommend the use of apoB instead of LDL-C as a predictor of CVD ([@b7-mmr-08-01-0260]--[@b9-mmr-08-01-0260]).

Cleaved fragments of lipoprotein(a) (LPA) protein are capable of attaching to atherosclerotic lesions and thus promote thrombogenesis ([@b10-mmr-08-01-0260],[@b11-mmr-08-01-0260]). Elevated levels of plasma LPA are associated with atherosclerosis ([@b12-mmr-08-01-0260]). *LPA* gene variants may contribute to the risk of CHD by regulating the level of lipids ([@b13-mmr-08-01-0260]). SNP rs7767084 of the *LPA* gene was observed to be associated with levels of LDL-C ([@b14-mmr-08-01-0260]) and CHD ([@b15-mmr-08-01-0260]). However, rs7767084 of the *LPA* gene was not associated with CHD risk in the Hispanic population ([@b16-mmr-08-01-0260]).

Lysosomal lipase A (LIPA) is able to catalyze the hydrolysis of cholesteryl esters and triglycerides. SNP rs2246942 of the *LIPA* gene was demonstrated to be significantly associated with the risk of CHD in European and South Asian populations ([@b17-mmr-08-01-0260]). A recent study observed a significant association between rs1412444 of the *LIPA* gene and risk of CHD in South Asian and European populations ([@b18-mmr-08-01-0260]).

The present study examined four gene variants involved in lipid metabolism: rs562338 and rs503662 of the *APOB* gene; rs7767084 of the *LPA* gene; and rs2246942 of the *LIPA* gene. We performed a case-control study to investigate their contribution to the risk of CHD in the Han Chinese population. A meta-analysis of three case-control studies among Han Chinese individuals was also performed to establish the role of *LPA* rs7767084 in CHD.

Materials and methods
=====================

Sample collection
-----------------

A total of 483 unrelated inpatients were enrolled from Lihuili Hospital (Ningbo, Zhejiang, China). In addition, 330 healthy individuals (including 86 males and 244 females; mean age, 63.44±9.21 years) who originated from Ningbo City (China) were recruited as healthy controls. Patients were diagnosed by standardized coronary angiography according to Seldinger's method ([@b19-mmr-08-01-0260]), and assessed by at least two independent cardiologists. Patients with CHD (n=290; 209 males and 81 females; mean age, 61.98±9.49 years) demonstrated at least one of the following criteria: i) ≥50% coronary artery occlusion of one or more major coronary arteries ([@b20-mmr-08-01-0260]); ii) a history of prior angioplasty; or iii) a history of coronary artery bypass surgery. Non-CHD controls (n=193; 98 males and 95 females; mean age, 58.65±9.36 years) with a \<50% occlusion in the major coronary artery and no atherosclerotic vascular disease were selected from the inpatient population. All samples were obtained from individuals of Han Chinese ethnicity originating from Ningbo, China. Subjects with congenital heart disease, cardiomyopathy and liver or renal diseases were excluded from the study. Blood samples were collected in 3.2% citrate sodium-treated tubes and then stored at −80°C. The protocol of our study was approved by the ethical committee of Lihuili Hospital (Ningbo, Zhejiang, China). Written informed consent was obtained from all patients.

SNP genotyping
--------------

Human genomic DNA was prepared from peripheral blood samples using the nucleic acid extraction automatic analyzer (Lab-Aid 820, Xiamen City, China) and was quantified using the PicoGreen^®^ double strand (dsDNA) DNA Quantification kit (Molecular Probes Inc., Eugene, USA). Amplification was performed on the ABI Geneamp^®^ PCR System 9700, Dual 384-Well Sample Block Module (Applied Biosystems, Foster City, CA) for the polymerase chain reaction (PCR). PCR conditions included an initial denaturation stage at 94°C for 15 sec, followed by 45 amplification cycles (including 94°C for 20 sec, 56°C for 30 sec and primer extension at 72°C for 1 min) and a final extension stage for 3 min at 72°C. Primer extension for genotyping was performed on the Sequenom^®^ Mass-ARRAY iPLEX^®^ (Sequenom, San Diego, CA, USA) platform according to the manufacturer's instructions ([@b21-mmr-08-01-0260]). The primer sequences of the four SNPs used for the PCR assays are shown in [Table I](#tI-mmr-08-01-0260){ref-type="table"}.

Meta-analysis
-------------

We systematically searched databases, including PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>) and the China National Knowledge Infrastructure (CNKI; <http://www.cnki.net/>) for all available case-control studies relating to rs7767084 of the *LPA* gene and CHD. We selected studies based on the following criteria: i) The study was an original study with an abstract in citation; ii) the study used a case-control or a prospective design; iii) the study contained complete data with genotype and allele frequencies; and iv) the genotype frequencies of controls were reported in Hardy-Weinberg equilibrium (HWE). Statistical heterogeneity between studies was estimated using the Q-test. An I^2^ value \>50% indicated a significant heterogeneity among the studies included in the meta-analysis ([@b22-mmr-08-01-0260]). A random-effects model based on the inverse-variance method was used for the studies with high heterogeneity. Publication bias was estimated using funnel plots ([@b23-mmr-08-01-0260]).

Statistical analysis
--------------------

HWE was analyzed using the Arlequin program (version 3.5) ([@b24-mmr-08-01-0260]). Genotype and allele frequencies were compared between CHD cases and each of the two controls using the PASW Statistics 18.0 software (SPSS, Inc., Somers, NY, USA). The odds ratio (OR) with 95% confidence interval (95% CI) were calculated using an online tool (<http://faculty.vassar.edu/lowry/odds2x2.html>). Power and Sample Size Calculation software (v3.0.43) was used to determine the power of the study ([@b25-mmr-08-01-0260]). Correlation between genotype and the extent of CHD disease was also performed using the PASW Statistics 18.0 software. Meta-analyses were performed using RevMan software (version 5.1, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011). P\<0.05 was considered to indicate a statistically significant result.

Results
=======

Genetic tests
-------------

No departure from HWE was observed for the four lipid metabolism gene variants. SNPs rs503662 and rs562338 of the *APOB* gene were extremely rare in our samples (minor allele frequencies \<1%), therefore they were not included in the further analysis. Genotype and allele frequencies of rs7767084 and rs2246942 are shown in [Table II](#tII-mmr-08-01-0260){ref-type="table"}. No significant association with CHD was observed for the two SNPs. Further genetic tests under the recessive and dominant inheritance models were performed for rs7767084 and rs2246942, and the results of these tests are shown in [Table III](#tIII-mmr-08-01-0260){ref-type="table"} and [Table IV](#tIV-mmr-08-01-0260){ref-type="table"}, respectively. In the recessive model, a significant association between the rs2246942-GG genotype and risk of CHD was detected (CHD cases versus healthy controls: P=0.04; OR=1.63; 95% CI=1.02--2.60).

CHD
---

CHD is the leading cause of human mortality worldwide. However, higher rates of CHD are observed in males compared with females across all age groups. In addition, coronary disease occurs up to 10 years later in females ([@b26-mmr-08-01-0260]). Due to the genetic and habitual differences between genders, we performed a breakdown association test by gender to examine whether gender as a factor may influence the contribution of SNPs to CHD risk. Subsequently, we identified a significant association at the genotype level ([Table V](#tV-mmr-08-01-0260){ref-type="table"}). Further tests under the dominant ([Table IV](#tIV-mmr-08-01-0260){ref-type="table"}) and recessive ([Table III](#tIII-mmr-08-01-0260){ref-type="table"}) models were also performed. In the recessive model, we observed a significant protective effect of rs7767084-CC against CHD in females (CHD cases versus non-CHD controls: P=0.04, OR=0.21, 95% CI=0.05--1.01; CHD cases versus healthy controls: P=0.02, OR=0.21, 95% CI=0.05--0.91). In addition, there was a correlation towards a significant association of rs2246942-GG with CHD in males under the recessive model (CHD cases versus healthy controls: P=0.06, OR=2.27, 95% CI=0.97--5.33). No significant association was identified in the dominant model.

In the CHD group, a correlation test was performed between the two gene variants and the number of coronary arteries with occlusion. No correlation between either of the two gene variants and CHD severity was observed ([Table VI](#tVI-mmr-08-01-0260){ref-type="table"}). For rs7767084 of the *LPA* gene, our meta-analysis included three case-control studies among the Han Chinese population ([Fig. 1](#f1-mmr-08-01-0260){ref-type="fig"}). The random-effects model was used since significant heterogeneity was observed among these studies (P\<10^−5^; I^2^=97%). The results of the meta-analysis indicated that rs7767084 was not associated with risk of CHD (P=0.83; df=2; Z=0.21; combined OR=0.93; 95% CI=0.47--1.85). There was no publication bias according to the funnel plot ([Fig. 2](#f2-mmr-08-01-0260){ref-type="fig"}).

Discussion
==========

Two SNPs of the *APOB* gene (rs562338 and rs503662) were detected at extremely low levels in our samples. According to the information in the online HapMap dataset, the minor allele frequencies in the HapMap-HCB (Han Chinese in Beijing) are 1.1% for rs562338 and 1.1% for rs503662, in contrast with 22.5% and 31.7% in the HapMap-CEU (CEPH; Utah residents with ancestry from northern and western Europe), respectively (<http://hapmap.ncbi.nlm.nih.gov/>). These findings support our data and implicate a significant ethnic difference for the two SNPs. We were unable to observe a significant association between rs7767084 and the risk of CHD in the case-control study and the subsequent meta-analysis. This negative result in the Chinese population agrees with the previous results of a large-scale case-control study in the Hispanic population ([@b16-mmr-08-01-0260]). Notably, a further breakdown test by gender demonstrated that the rs7767084-CC genotype acts as a protective factor against CHD in females under the recessive model ([Table II](#tII-mmr-08-01-0260){ref-type="table"}). This gender-dependent result is novel and a further study on a larger scale is warranted. In the present study, genotype rs2246942-GG of the *LIPA* gene was shown to increase the risk of CHD by 63% in the recessive model (CHD cases versus healthy controls: P=0.04). In addition, a correlation between genotype rs2246942-GG with an increased risk of CHD was observed in males under the recessive model (CHD cases versus healthy controls: P=0.06, OR=2.27). Another SNP of the *LIPA* gene (rs2246833) is located only 968 bp away from rs2246942, and was previously implicated with an increased risk of CHD in European and South Asian populations ([@b17-mmr-08-01-0260]). Our results suggest that rs2246942 of the *LIPA* gene is likely to contribute to the risk of CHD in the male Chinese population under the recessive model.

ApoB regulates the concentration of plasma LDL-C and is directly associated with CHD ([@b27-mmr-08-01-0260]). Recent studies have shown that *APOB* polymorphisms (XbaI, MspI and 3′VNTR) are associated with the risk of CHD in the Chinese population ([@b28-mmr-08-01-0260],[@b29-mmr-08-01-0260]). LPA may contribute to CVD through complex mechanisms that involve proatherogenic and prothrombotic pathways ([@b30-mmr-08-01-0260],[@b31-mmr-08-01-0260]). LPA accumulates in the arterial wall of patients with CHD ([@b32-mmr-08-01-0260]) and contributes to cholesterol deposition ([@b33-mmr-08-01-0260]). Previous studies have reported that SNPs (rs10455872 and rs3798220) in the *LPA* region are associated with a higher risk of CHD ([@b34-mmr-08-01-0260]--[@b37-mmr-08-01-0260]). The *LIPA* gene encodes lysosomal acid lipase (LAL) ([@b38-mmr-08-01-0260],[@b39-mmr-08-01-0260]), which hydrolyzes cholesteryl esters and triglycerides delivered to the lysosome. A loss of LAL function results in the accumulation of triglycerides and cholesteryl esters in the cell, and eventually causes the formation of atherosclerotic plaques ([@b40-mmr-08-01-0260]). *LIPA* gene mutations may cause the cholesteryl ester storage disease and Wolman's disease ([@b41-mmr-08-01-0260]), which often accompany premature CVD.

CHD is a complex disease involving numerous genes. Although a total of 813 Han Chinese individuals were included in this study, it is not well powered for analyses, demonstrating that the power of the test under the recessive model is 53.5% for rs2246942-GG and 69% for rs7767084-CC in females. Meanwhile, the ratio of males and females enrolled in our sample requires adjustment to ensure a more balanced case-control study. All P-values provided in this study were not corrected by the number of tests, thus there is a chance that this study may include false positive results.

In conclusion, a gender-dependent association between rs7767084 of the *LPA* gene and CHD was observed in the female Chinese population under the recessive model. In addition, a possible explanation for the contribution of rs2246942-GG of the *LIPA* gene to the risk of CHD in the male Chinese population under the recessive model was identified.
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###### 

Primer sequences for the four SNPs.

  SNP         Primer type      Primer sequence
  ----------- ---------------- --------------------------------
  rs562338    1st PCR primer   ACGTTGGATGCAGCCTAAATGTTCATTGTC
              2nd PCR primer   ACGTTGGATGCCATGGTTTGCATACATCAC
  rs503662    1st PCR primer   ACGTTGGATGGATAGTATGTGTGGCAGAAG
              2nd PCR primer   ACGTTGGATGACCCTGAATCTAACACAATC
  rs7767084   1st PCR primer   ACGTTGGATGTTGGGCTGGTCACTTTTGTC
              2nd PCR primer   ACGTTGGATGGTGACTCCAGAATGAAGCTC
  rs2246942   1st PCR primer   ACGTTGGATGGGAAAGATCTCCAAGATAT
              2nd PCR primer   ACGTTGGATGCTTATTTTTCCCTTGCCTCC

SNP, single nucleotide polymorphism.

###### 

Distribution of genotype and allele frequencies between CHD cases and the two control groups.

  A, SNP rs7767084                                                                                                                                         
  ------------------ -------------------------- ------------ ----------- ------ ------------------------ ------ ------------ ------------ ------ --------- -------------------
  CHD cases          149 (51.4)                 121 (41.7)   20 (6.9)                                    0.49   161 (27.8)   419 (72.2)                    
  Control 1          105 (54.4)                 74 (38.3)    14 (7.3)    0.55   0.76                     0.85   102 (26.4)   284 (73.6)   0.21   0.65      1.07 (0.80, 1.43)
  Control 2          171 (51.8)                 127 (38.5)   32 (9.7)    1.85   0.40                     0.24   191 (28.9)   469 (71.1)   0.21   0.65      0.94 (0.74, 1.21)
                                                                                                                                                           
  B, SNP rs2246942                                                                                                                                         
                                                                                                                                                           
                     Genotype frequencies (%)                                   Allele frequencies (%)                                                     
                                                                                                                                                           
  Group              AA                         AG           GG          χ^2^   P-value                  HWE    G            A            χ^2^   P-value   OR (95% CI)
                                                                                                                                                           
  CHD cases          115 (39.7)                 128 (44.1)   47 (16.2)                                   0.26   222 (38.3)   358 (61.7)                    
  Control 1          69 (35.8)                  96 (49.7)    28 (14.5)   1.46   0.48                     0.56   152 (39.4)   234 (60.6)   0.12   0.73      0.96 (0.73, 1.24)
  Control 2          136 (41.3)                 158 (48.0)   35 (10.7)   4.22   0.12                     0.27   228 (34.7)   430 (65.3)   1.75   0.19      1.17 (0.93, 1.48)

Control 1, non-CHD controls; control 2, healthy controls; CHD, coronary heart disease; SNP, single nucleotide polymorphism; HWE, Hardy-Weinberg equilibrium; OR, odds ratio; CI, confidence interval.

###### 

Genetic analysis of the two gene variants under the recessive model.

  A, SNP rs7767084                                            
  ------------------ ---------------------- ------- --------- -------------------
  Total                                                       
   CHD cases         20                     270               
   Control 1         14                     179     0.88      0.95 (0.47, 1.92)
   Control 2         32                     298     0.21      0.69 (0.39, 1.24)
  Male                                                        
   CHD cases         18                     191               
   Control 1         4                      94      0.15      2.21 (0.73, 6.73)
   Control 2         6                      80      0.64      1.26 (0.48, 3.28)
  Female                                                      
   CHD cases         2                      79                
   Control 1         10                     85      0.04      0.21 (0.05, 1.01)
   Control 2         26                     218     0.02      0.21 (0.05, 0.91)
                                                              
  B, SNP rs2246942                                            
                                                              
                     Genotype frequencies                     
                                                              
  Group              GG                     AA+AG   P-value   OR (95% CI)
                                                              
  Total                                                       
   CHD cases         47                     243               
   Control 1         28                     165     0.61      1.14 (0.69, 1.89)
   Control 2         35                     294     0.04      1.63 (1.02, 2.60)
  Male                                                        
   CHD cases         35                     174               
   Control 1         14                     84      0.58      1.21 (0.62, 2.36)
   Control 2         7                      79      0.06      2.27 (0.97, 5.33)
  Female                                                      
   CHD cases         12                     69                
   Control 1         14                     81      0.99      1.01 (0.44, 2.32)
   Control 2         28                     215     0.43      1.33 (0.64, 2.77)

Control 1, non-CHD controls; control 2, healthy controls; CHD, coronary heart disease; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Genetic analysis of the two gene variants under the dominant model.

  A, SNP rs7767084                                          
  ------------------ ---------------------- ----- --------- -------------------
  Total                                                     
   CHD cases         141                    149             
   Control 1         88                     105   0.51      1.13 (0.78, 1.63)
   Control 2         159                    171   0.91      1.02 (0.74, 1.40)
  Male                                                      
   CHD cases         98                     111             
   Control 1         46                     52    0.99      1.00 (0.62, 1.61)
   Control 2         38                     48    0.67      1.11 (0.67, 1.85)
  Female                                                    
   CHD cases         43                     38              
   Control 1         42                     53    0.24      1.43 (0.79, 2.59)
   Control 2         121                    123   0.59      1.15 (0.69, 1.90)
                                                            
  B, SNP rs2246942                                          
                                                            
                     Genotype frequencies                   
                                                            
  Group              AG+GG                  AA    P-value   OR (95% CI)
                                                            
  Total                                                     
   CHD cases         175                    115             
   Control 1         124                    69    0.39      0.85 (0.58, 1.23)
   Control 2         193                    136   0.67      1.07 (0.78, 1.48)
  Male                                                      
   CHD cases         118                    91              
   Control 1         64                     34    0.14      0.69 (0.42, 1.13)
   Control 2         49                     37    0.93      0.98 (0.59, 1.63)
  Female                                                    
   CHD cases         57                     24              
   Control 1         60                     35    0.31      1.38 (0.73, 2.61)
   Control 2         144                    99    0.07      1.63 (0.95, 2.81)

Control 1, non-CHD controls; control 2, healthy controls; CHD, coronary heart disease; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Genetic testing of the two gene variants stratified by gender.

  A, SNP rs7767084                                                                                                               
  ------------------ -------------------------- ----- ---- ------- ------------------------ ------ ----- ----- ------- --------- -------------------
  Male                                                                                                                           
   CHD cases         111                        80    18                                    0.51   116   302                     
   Control 1         52                         42    4    2.26    0.32                     0.21   50    146   0.34    0.56      1.12 (0.76, 1.65)
   Control 2         48                         32    6    0.30    0.86                     0.83   44    128   0.29    0.59      1.12 (0.75, 1.67)
  Female                                                                                                                         
   CHD cases         38                         41    2                                     0.02   45    117                     
   Control 1         53                         32    10   7.85    0.02                     0.14   52    138   0.01    0.93      1.02 (0.64, 1.63)
   Control 2         123                        95    26   6.86    0.03                     0.24   147   341   0.32    0.57      0.89 (0.60, 1.32)
                                                                                                                                 
  B, SNP rs2246942                                                                                                               
                                                                                                                                 
                     Genotype frequencies (%)                      Allele frequencies (%)                                        
                                                                                                                                 
  Group              AA                         AG    GG   χ ^2^   P-value                  HWE    G     A     χ ^2^   P-value   OR (95% CI)
                                                                                                                                 
  Male                                                                                                                           
   CHD cases         91                         83    35                                    0.04   153   265                     
   Control 1         34                         50    14   3.51    0.17                     0.52   78    118   0.58    0.45      0.87 (0.62, 1.24)
   Control 2         37                         42    7    4.37    0.11                     0.30   56    116   0.87    0.35      1.20 (0.82, 1.74)
  Female                                                                                                                         
   CHD cases         24                         45    12                                    0.22   69    93                      
   Control 1         35                         46    14   1.11    0.57                     0.86   74    116   0.48    0.49      1.16 (0.76, 1.78)
   Control 2         99                         116   28   3.26    0.20                     0.49   172   314   2.70    0.10      1.35 (0.94, 1.95)

Control 1, non-CHD controls; control 2, healthy controls; CHD, coronary heart disease; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

###### 

Correlation between two gene variants and the number of stenoses in CHD cases under the dominant and recessive models.

                     Number of stenoses             
  ------------ ----- -------------------- ---- ---- ------
  Dominant                                          
   rs7767084                                        
    TT         129   43                   32   54   0.23
    TC+CC      121   51                   25   45   
   rs2246942                                        
    AA         98    34                   24   40   0.56
    AG+GG      152   60                   33   59   
  Recessive                                         
   rs7767084                                        
    CC         15    5                    1    9    0.26
    TC+TT      235   89                   56   90   
   rs2246942                                        
    GG         41    18                   13   10   0.08
    AG+AA      209   76                   44   89   

CHD, coronary heart disease.
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